Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/26/2004 3:51:01 AM
	of 3044

Superior In-Hospital and 30-Day Outcomes with Abciximab Versus Eptifibatide: A Contemporary Analysis of 495 Consecutive Percutaneous Coronary Interventions Posted 12/23/2004 [The pressure on Integrilin continues. This study seems to indicate that the use of Reopro might well give more favorable outcomes than Integrilin. For the full article at Medscape, use the link below.] Efthymios N. Deliargyris, MD; Bharathi Upadhya, MD; Robert J. Applegate, MD; Michael A. Kutcher, MD; Sanjay K Gandhi, MD; David C. Sane, MD Abstract and Introduction Background: Both abciximab (AB) and eptifibatide (EP) are approved for use during percutaneous coronary intervention (PCI) but comparative data between the 2 agents are limited. Methods: We compared in-hospital and 30-day outcomes of contemporary 495 consecutive PCIs performed by a single operator between July 2001 and November 02 with AB and EP (242 with AB and 253 with EP). Cardiogenic shock patients who underwent a second procedure within 30 days from their first procedure were excluded. Selection of glycoprotein IIb/IIIa was at the operator's discretion. The initial 444 cases were performed with unfractionated heparin and the last 51 with bivalirudin. Results: AB cases comprised a higher risk group with more patients with diabetes, peripheral vascular disease, ST-elevation myocardial infarction and renal failure (p < 0.05 for each) and more rotablator use and longer lesions (p < 0.01 for each). AB was associated with less in-hospital (4.6 versus 12.3%; OR: 0.34; 95% CI: 0.17–0.7; p = 0.004) as well as 30-day (5.5 versus 14%; OR: 0.37; 95% CI: 0.19–0.71; p = 0.003]) major adverse cardiac events (sum of death, MI, urgent revascularization, all bleeding and stroke). Conclusion: Despite its use in higher risk PCI patients, AB resulted in superior short-term outcomes compared with EP. Our data suggest that significant efficacy differences may exist between these 2 agents and that a randomized comparison is warranted. medscape.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next